Clinical trials and biomarker development with molecularly targeted agents and radiotherapy

被引：0
|
作者：
Neesha Dhani
Lillian L. Siu
机构：
[1] University of Toronto,Princess Margaret Hospital, Division of Medical Oncology and Hematology, Department of Medicine
[2] Division of Medical Oncology and Hematology,Princess Margaret Hospital
来源：
Cancer and Metastasis Reviews | 2008年 / 27卷
关键词：
Clinical trials; Biomarker; Radiotherapy; Genomics; Prognosis; Pharmacokinetics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：339 / 349
页数：10
相关论文
共 50 条
  • [1] Clinical trials and biomarker development with molecularly targeted agents and radiotherapy
    Dhani, Neesha
    Siu, Lillian L.
    CANCER AND METASTASIS REVIEWS, 2008, 27 (03) : 339 - 349
  • [2] Drug development in oncology: classical cytotoxics and molecularly targeted agents
    Kummar, Shivaani
    Gutierrez, Martin
    Doroshow, James H.
    Murgo, Anthony J.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 62 (01) : 15 - 26
  • [3] Radiosensitising agents for the radiotherapy of cancer: novel molecularly targeted approaches
    Dumont, Francis
    Altmeyer, Anais
    Bischoff, Pierre
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2009, 19 (06) : 775 - 799
  • [4] The Clinical Development of Molecularly Targeted Agents in Combination With Radiation Therapy: A Pharmaceutical Perspective
    Ataman, Ozlem U.
    Sambrook, Sally J.
    Wilks, Chris
    Lloyd, Andrew
    Taylor, Amanda E.
    Wedge, Stephen R.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (04): : E447 - E454
  • [5] Dose-finding designs for trials of molecularly targeted agents and immunotherapies
    Chiuzan, Cody
    Shtaynberger, Jonathan
    Manji, Gulam A.
    Duong, Jimmy K.
    Schwartz, Gary K.
    Ivanova, Anastasia
    Lee, Shing M.
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2017, 27 (03) : 477 - 494
  • [6] Creatinine Clearance Is Associated with Toxicity from Molecularly Targeted Agents in Phase I Trials
    Basu, B.
    Vitfell-Pedersen, J.
    Garcia, V. Moreno
    Puglisi, M.
    Tjokrowidjaja, A.
    Shah, K.
    Malvankar, S.
    Anghan, B.
    de Bono, J. S.
    Kaye, S. B.
    Molife, L. R.
    Banerji, U.
    ONCOLOGY, 2012, 83 (04) : 177 - 182
  • [7] SEAMLESS PHASE I/II ADAPTIVE DESIGN FOR ONCOLOGY TRIALS OF MOLECULARLY TARGETED AGENTS
    Wages, Nolan A.
    Tait, Christopher
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2015, 25 (05) : 903 - 920
  • [8] Targeted agents in GI radiotherapy: Clinical efficacy and side effects
    Fokas, Emmanouil
    Roedel, Claus
    BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2016, 30 (04) : 537 - 549
  • [9] The State of Preclinical Modeling for Early Phase Cancer Trials Using Molecularly Targeted Agents with Radiation
    Hong, Julie A.
    Vikram, Bhadrasian
    Buchsbaum, Jeffrey
    Capala, Jacek
    Livinski, Alicia
    Teicher, Beverly
    Prasanna, Pataje
    Ahmed, Mansoor M.
    Obcemea, Ceferino
    Coleman, C. Norman
    Espey, Michael Graham
    RADIATION RESEARCH, 2022, 198 (06) : 625 - 631
  • [10] On the efficiency of targeted clinical trials
    Maitournam, A
    Simon, R
    STATISTICS IN MEDICINE, 2005, 24 (03) : 329 - 339
12345